1. Executive Summary (Confidence: High)

Novartis has undergone a strategic transformation to become a "pure-play" innovative medicines company, divesting its Sandoz generics business to focus on high-value, patent-protected therapies.^[12] A central pillar of its long-term strategy is the "Diseases of Aging and Regenerative medicine" (DARe) group, which treats aging as a multi-system biological process rather than a collection of separate diseases.^[26] Driven by its proprietary "Regeneration Engine," Novartis is developing a pipeline that targets mitochondrial dysfunction, DNA repair, and extracellular matrix (ECM) alterations.^[26] With Q3 2025 net sales of USD 13.9 billion and a core operating income margin of 39.3%, the company is a dominant force in the longevity ecosystem, prioritizing advanced platforms like radioligand therapy, xRNA, and gene therapy.^[12]